<p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - 获取免费报告) 在周二的交易中下跌了 7.6%。该公司的股价最低曾达到 11.43 美元，最后交易价为 11.95 美元。在午盘交易中，共成交了 1,110,178 股，较平均交易量 602,640 股增加了 84%。该股票此前收盘价为 12.93 美元。</p>
<p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>CGEM 已成为几份研究报告的主题。Wedbush 在 11 月 20 日的研究报告中重申了对 Cullinan Therapeutics 的 &#34;跑赢大盘&#34; 评级，并给出了 25.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Cullinan Therapeutics 的 &#34;卖出 (e+)&#34; 评级。摩根士丹利将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并在 8 月 18 日的报告中对该股票设定了 &#34;增持&#34; 评级。HC Wainwright 在 11 月 20 日的研究报告中将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，New Street Research 在周四的研究报告中设定了 26.00 美元的目标价。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 27.00 美元。</p>
<p><strong>查看我们关于 Cullinan Therapeutics 的最新报告</strong></p>
<h2>Cullinan Therapeutics 股价下跌 10.5%</h2>
<p>该股票的市值为 6.8351 亿美元，市盈率为-3.50，贝塔值为-0.07。该公司的 50 日移动平均线为 7.47 美元，200 日移动平均线为 7.69 美元。</p>
<p>Cullinan Therapeutics (NASDAQ:CGEM - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告季度每股收益为 (-0.77) 美元，超出分析师共识预期的 (-0.95) 美元，超出幅度为 0.18 美元。整体来看，卖方分析师预测 Cullinan Therapeutics, Inc. 在当前财年将发布-3.04 美元的每股收益。</p>
<h2>Cullinan Therapeutics 的内部交易</h2>
<p>在相关消息中，主要股东 Lynx1 Capital Management Lp 于 10 月 28 日以 165,667 股的价格收购了该公司的股票。该股票的平均收购价格为每股 8.40 美元，总价值为 1,391,602.80 美元。交易完成后，内部人士持有该公司 8,963,500 股股票，估值约为 75,293,400 美元。这代表了他们持股比例的 1.88% 的增加。该购买在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。在上个季度，内部人士共收购了价值 13,325,286 美元的 1,874,057 股公司股票。公司内部人士持有公司股票的 7.16%。</p>
<h2>对 Cullinan Therapeutics 的对冲基金看法</h2>
<p>一些对冲基金最近对该公司的持仓进行了调整。Brooklyn Investment Group 在第一季度收购了 Cullinan Therapeutics 的新股份，价值约 34,000 美元。SG Americas Securities LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 62,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Cullinan Therapeutics 的持股增加了 44.6%。Tower Research Capital LLC TRC 目前持有该公司 8,182 股股票，价值 62,000 美元，此前在该期间内又购买了 2,523 股。Inscription Capital LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 67,000 美元。最后，Compass Ion Advisors LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 82,000 美元。机构投资者和对冲基金持有公司 86.31% 的股票。</p>
<h2>Cullinan Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Cullinan Therapeutics, Inc. 是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Cullinan Therapeutics</li>
<li>什么是财报？</li>
<li>六旗的新领导者：过山车结束了吗？</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>百度可能成为全球人工智能的黑马的三个理由</li>
<li>什么是空头头寸？如何使用它</li>
<li>投资基础设施：三只人工智能基础设施股票</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
<p>在考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cullinan Therapeutics 并不在名单上。</p>
<p>虽然 Cullinan Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGEM

<p>Cullinan Therapeutics（纳斯达克代码：CGEM）股价下跌 7.6%，至 11.95 美元，交易量上升 84%。分析师的评级意见不一：Wedbush 和 HC Wainwright 给予 “买入” 评级，目标价格分别为 25 美元和 26 美元，而 Weiss Ratings 则给予 “卖出” 评级。该股票的共识评级为 “适度买入”，目标价格为 27 美元。内部人士和对冲基金的活动显示出兴趣增加，内部人士持有 7.16% 的股份，机构投资者持有 86.31% 的股份</p>

<p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) traded down 7.6% during trading on Tuesday . The company traded as low as $11.43 and last traded at $11.95. 1,110,178 shares traded hands during mid-day trading, an increase of 84% from the average session volume of 602,640 shares. The stock had previously closed at $12.93.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc. (NASDAQ:CGEM - 获取免费报告) 在周二的交易中下跌了 7.6%。该公司的股价最低曾达到 11.43 美元，最后交易价为 11.95 美元。在午盘交易中，共成交了 1,110,178 股，较平均交易量 602,640 股增加了 84%。该股票此前收盘价为 12.93 美元。</p>
</div><p>Get <strong>Cullinan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>CGEM has been the topic of several research reports. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $25.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, November 20th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Cullinan Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley dropped their price objective on Cullinan Therapeutics from $35.00 to $28.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, August 18th. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 20th. Finally, New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $27.00.</p>
<div class="lb-trans"><p>CGEM 已成为几份研究报告的主题。Wedbush 在 11 月 20 日的研究报告中重申了对 Cullinan Therapeutics 的 &#34;跑赢大盘&#34; 评级，并给出了 25.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Cullinan Therapeutics 的 &#34;卖出 (e+)&#34; 评级。摩根士丹利将 Cullinan Therapeutics 的目标价从 35.00 美元下调至 28.00 美元，并在 8 月 18 日的报告中对该股票设定了 &#34;增持&#34; 评级。HC Wainwright 在 11 月 20 日的研究报告中将 Cullinan Therapeutics 的目标价从 24.00 美元上调至 26.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，New Street Research 在周四的研究报告中设定了 26.00 美元的目标价。六位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 27.00 美元。</p>
</div><p><strong>View Our Latest Report on Cullinan Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cullinan Therapeutics 的最新报告</strong></p>
</div><h2>Cullinan Therapeutics Trading Down 10.5%</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 股价下跌 10.5%</h2>
</div><p>The stock has a market capitalization of $683.51 million, a price-to-earnings ratio of -3.50 and a beta of -0.07. The company has a fifty day moving average of $7.47 and a two-hundred day moving average of $7.69.</p>
<div class="lb-trans"><p>该股票的市值为 6.8351 亿美元，市盈率为-3.50，贝塔值为-0.07。该公司的 50 日移动平均线为 7.47 美元，200 日移动平均线为 7.69 美元。</p>
</div><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18. As a group, sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cullinan Therapeutics (NASDAQ:CGEM - 获取免费报告) 最近于 11 月 6 日发布了季度财报。该公司报告季度每股收益为 (-0.77) 美元，超出分析师共识预期的 (-0.95) 美元，超出幅度为 0.18 美元。整体来看，卖方分析师预测 Cullinan Therapeutics, Inc. 在当前财年将发布-3.04 美元的每股收益。</p>
</div><h2>Insider Transactions at Cullinan Therapeutics</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 的内部交易</h2>
</div><p>In related news, major shareholder Lynx1 Capital Management Lp acquired 165,667 shares of the business's stock in a transaction dated Tuesday, October 28th. The stock was acquired at an average price of $8.40 per share, with a total value of $1,391,602.80. Following the completion of the transaction, the insider owned 8,963,500 shares of the company's stock, valued at approximately $75,293,400. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 1,874,057 shares of company stock valued at $13,325,286. Company insiders own 7.16% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 Lynx1 Capital Management Lp 于 10 月 28 日以 165,667 股的价格收购了该公司的股票。该股票的平均收购价格为每股 8.40 美元，总价值为 1,391,602.80 美元。交易完成后，内部人士持有该公司 8,963,500 股股票，估值约为 75,293,400 美元。这代表了他们持股比例的 1.88% 的增加。该购买在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。在上个季度，内部人士共收购了价值 13,325,286 美元的 1,874,057 股公司股票。公司内部人士持有公司股票的 7.16%。</p>
</div><h2>Hedge Funds Weigh In On Cullinan Therapeutics</h2>
<div class="lb-trans"><h2>对 Cullinan Therapeutics 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new stake in shares of Cullinan Therapeutics during the 1st quarter valued at about $34,000. SG Americas Securities LLC acquired a new position in Cullinan Therapeutics in the third quarter worth about $62,000. Tower Research Capital LLC TRC lifted its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the period. Inscription Capital LLC acquired a new stake in Cullinan Therapeutics during the third quarter valued at approximately $67,000. Finally, Compass Ion Advisors LLC bought a new stake in shares of Cullinan Therapeutics in the 3rd quarter valued at approximately $82,000. Institutional investors and hedge funds own 86.31% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对该公司的持仓进行了调整。Brooklyn Investment Group 在第一季度收购了 Cullinan Therapeutics 的新股份，价值约 34,000 美元。SG Americas Securities LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 62,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Cullinan Therapeutics 的持股增加了 44.6%。Tower Research Capital LLC TRC 目前持有该公司 8,182 股股票，价值 62,000 美元，此前在该期间内又购买了 2,523 股。Inscription Capital LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 67,000 美元。最后，Compass Ion Advisors LLC 在第三季度收购了 Cullinan Therapeutics 的新股份，价值约 82,000 美元。机构投资者和对冲基金持有公司 86.31% 的股票。</p>
</div><h2>Cullinan Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc. 是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Cullinan Therapeutics</li>
<li>What Are Earnings Reports?</li>
<li>A New Leader at Six Flags: Is the Roller Coaster Over?</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>3 Reasons Baidu Could Be the Dark Horse of Global AI</li>
<li>What is Short Interest? How to Use It</li>
<li>Betting on the Backbone: 3 AI Infrastructure Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Cullinan Therapeutics</li>
<li>什么是财报？</li>
<li>六旗的新领导者：过山车结束了吗？</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>百度可能成为全球人工智能的黑马的三个理由</li>
<li>什么是空头头寸？如何使用它</li>
<li>投资基础设施：三只人工智能基础设施股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
</div><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cullinan Therapeutics 并不在名单上。</p>
</div><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cullinan Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullinan Therapeutics（纳斯达克股票代码：CGEM）股价下跌 7.6% - 你是否应该卖出？